HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
ADIL Adial Pharmaceuticals
- 0.7412
- -0.0468-5.94%
Close Feb 14 16:00 ET
- 0.7410
- -0.0002-0.03%
Post 20:01 ET
4.80MMarket Cap-0.22P/E (TTM)
0.7753High0.7183Low83.76KVolume0.7604Open0.7880Pre Close62.60KTurnover1.39%Turnover RatioLossP/E (Static)6.47MShares4.169952wk High0.82P/B4.46MFloat Cap0.715152wk Low--Dividend TTM6.02MShs Float236.0000Historical High--Div YieldTTM7.23%Amplitude0.7151Historical Low0.7470Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Adial Pharmaceuticals Stock Forum
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded New U.S Patent Covering Genotype-Specific Treatment Of Opioid -Related Disorders
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEV...
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Wednesday, 29th January at 9:00 am
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
Adial's formulation exhibited predictable bioavailability relative to the reference standard; near-micro...
Adial
Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
No comment yet